Target Product Profiles: Physician Insights on Key Attributes - Benign Prostatic Hyperplasia, A drug with lower incidence of sexual side effects than tamsulosin for the treatment of benign prostatic hyperplasia.

Table of Contents

• Introduction
  • Using Target Product Profi les in Your Market Strategy
  • Report Contents
  • Target Product Profi le Methodology
• Etiology and Pathophysiology
  • Overview
  • Anatomy
  • Pathophysiology
    • Androgens
    • Estrogen
    • Estrogen/Androgen Ratio
    • Gonadotropic Hormones
    • Vitamin D3
    • Insulin-Like Growth Factor
    • Other Growth Factors and Peptides
    • Nitric Oxide
  • Etiology
    • Genotype
    • Cellular Senescence
    • Infl ammation
    • Autonomic Hyperactivity
    • Metabolic Syndrome
    • Activation of Stem Cells
• Target Product Profi le Discussion-Benign Prostatic Hyperplasia
  • Target Product Profi le Summary for Benign Prostatic Hyperplasia-2011
  • Assessing Drug Development Opportunities
  • Physician Survey Results
    • Effi cacy
    • Safety and Tolerability
    • Delivery
    • Estimated Patient Share
  • Pricing Potential
  • Forecasted 2016 Pricing Environment
  • Competitors to Watch
  • Emerging Product Profi le